POOR RESPONSE TO INTENSIVE CHEMOTHERAPY IN DE-NOVO ACUTE MYELOID-LEUKEMIA WITH TRILINEAGE MYELODYSPLASIA

Citation
K. Kuriyama et al., POOR RESPONSE TO INTENSIVE CHEMOTHERAPY IN DE-NOVO ACUTE MYELOID-LEUKEMIA WITH TRILINEAGE MYELODYSPLASIA, British Journal of Haematology, 86(4), 1994, pp. 767-773
Citations number
34
Categorie Soggetti
Hematology
ISSN journal
00071048
Volume
86
Issue
4
Year of publication
1994
Pages
767 - 773
Database
ISI
SICI code
0007-1048(1994)86:4<767:PRTICI>2.0.ZU;2-L
Abstract
The findings of morphologically dysplastic features in haemopoietic ce lls in de novo acute myeloid leukaemia (AML) has been named AML with t rilineage myelodysplasia (AML/TMDS). We analysed the clinical data, ka ryotypes, and treatment outcomes of 230 de novo AML patients treated w ith the Japan Adult Leukaemia Study Group AML-87 protocol. 40 (17%) pa tients had AML/TMDS. Platelet count was significantly higher (P=0.006) and bone marrow blasts were fewer (P=0.01) in the AML/TMDS group than in the AML without TMDS. Abnormal karyotype was shown in 12/30 patien ts (40%) analysed. The complete remission (CR) rate for AML/TMDS was s ignificantly lower than AML without TMDS (63% v 81%) (P=0.01). The ove rall survival curves showed that the 40 patients with TMDS had a signi ficantly worse survival thanthe 190 without TMDS (P=0.0005). AML/TMDS also showed significantly worse disease-free survival (DFS) (P=0.0001) . Multivariate analysis revealed that the absence of TMDS in AML was t he most significant factor in obtaining CR (P=0.01) and a significant factor in predicting longer DFS (P=0.04). Our data suggest that AML/TM DS responds poorly to intensive chemotherapy. Further study is require d to determine the best treatment strategy for AML/TMDS and the biolog ical differences between AML/TMDS and other types of AML.